220 related articles for article (PubMed ID: 21921047)
41. Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia.
Jalali S; Shi J; Buko A; Ahsan N; Paludo J; Serres M; Wellik LE; Abeykoon J; Kim H; Tang X; Yang ZZ; Novak AJ; Witzig TE; Ansell SM
Redox Biol; 2020 Sep; 36():101657. PubMed ID: 32763516
[TBL] [Abstract][Full Text] [Related]
42. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Naderi N; Yang DT
Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
[TBL] [Abstract][Full Text] [Related]
43. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
[TBL] [Abstract][Full Text] [Related]
44. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
45. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
[TBL] [Abstract][Full Text] [Related]
46. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
[TBL] [Abstract][Full Text] [Related]
47. The cellular origin and malignant transformation of Waldenström macroglobulinemia.
Paiva B; Corchete LA; Vidriales MB; García-Sanz R; Perez JJ; Aires-Mejia I; Sanchez ML; Barcena P; Alignani D; Jimenez C; Sarasquete ME; Mateos MV; Ocio EM; Puig N; Escalante F; Hernández J; Cuello R; García de Coca A; Sierra M; Montes MC; González-López TJ; Galende J; Bárez A; Alonso J; Pardal E; Orfao A; Gutierrez NC; San Miguel JF
Blood; 2015 Apr; 125(15):2370-80. PubMed ID: 25655603
[TBL] [Abstract][Full Text] [Related]
48. C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment.
Urata S; Izumi K; Hiratsuka K; Maolake A; Natsagdorj A; Shigehara K; Iwamoto H; Kadomoto S; Makino T; Naito R; Kadono Y; Lin WJ; Wufuer G; Narimoto K; Mizokami A
Cancer Sci; 2018 Mar; 109(3):724-731. PubMed ID: 29288523
[TBL] [Abstract][Full Text] [Related]
49. Square IgM crystals in bone marrow in Waldenström macroglobulinaemia.
Erdem N; Ulu I; Miskioglu HM; Isisag A; Aydogdu I
Br J Haematol; 2016 Jul; 174(1):8. PubMed ID: 27173898
[No Abstract] [Full Text] [Related]
50. The malignant clone in Waldenstrom's macroglobulinemia.
Kriangkum J; Taylor BJ; Mant MJ; Treon SP; Belch AR; Pilarski LM
Semin Oncol; 2003 Apr; 30(2):132-5. PubMed ID: 12720122
[TBL] [Abstract][Full Text] [Related]
51. The bone marrow niche in Waldenström's macroglobulinemia.
Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa G; Roccaro A
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):118-20. PubMed ID: 21454209
[TBL] [Abstract][Full Text] [Related]
52. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
53. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
54. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.
Kriangkum J; Taylor BJ; Strachan E; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2006 Apr; 107(7):2920-7. PubMed ID: 16317092
[TBL] [Abstract][Full Text] [Related]
55. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment.
Li X; Han QC; Yu C; Luo YC; Wang F; Sun XH; Gao YQ; Tan WF; Xia Q
J Dig Dis; 2021 Jul; 22(7):433-441. PubMed ID: 33978316
[TBL] [Abstract][Full Text] [Related]
56. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
57. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.
Sacco A; Desantis V; Celay J; Giustini V; Rigali F; Savino FD; Cea M; Soncini D; Cagnetta A; Solimando AG; D'Aliberti D; Spinelli S; Ramazzotti D; Almici C; Todoerti K; Neri A; Anastasia A; Tucci A; Motta M; Chiarini M; Kawano Y; Martinez-Climent JA; Piazza R; Roccaro AM
Blood; 2023 May; 141(21):2615-2628. PubMed ID: 36735903
[TBL] [Abstract][Full Text] [Related]
58. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
[TBL] [Abstract][Full Text] [Related]
59. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
[TBL] [Abstract][Full Text] [Related]
60. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia.
Hatzimichael EC; Christou L; Bai M; Kolios G; Kefala L; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):1-6. PubMed ID: 11168500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
